61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit